Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Neumifil in Healthy Subjects
NCT05093530Phase 1Completed
- Sponsor
- Pneumagen
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Inhalation Devices, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEX17 in coronavirus disease 2019 (COVID-19) and viral respiratory tract infection (4 arms), sponsored by Pneumagen. Primary endpoints: Treatment Emergent Adverse Events and Clinically Significant Changes in Safety Tests. Started Oct 2021; status: completed.
02
Drugs
HEX17
03
Conditions
coronavirus disease 2019 (COVID-19)viral respiratory tract infection
Beyond the preview
Go deeper on NCT05093530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093530.